Science Explorer Back to mapMap
Discussion
Company · Solna · Sweden

Asarina Pharma (Sweden)

asarinapharma.comROR OpenAlex
Research works
14
▲ 876% vs 2018-21
Citations
197
14.5 per fractional work
Top-10% rate
16.4%
all institutions 10.0%
Open access
63%
world 40%
International
46%
world 18%
Asarina Pharma (Sweden)

Not ranked overall: Asarina Pharma (Sweden) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Asarina Pharma (Sweden) work in?

In all years, 46% of research at Asarina Pharma (Sweden) is in Health Sciences, 38% in Life Sciences. Its largest fields are Medicine (45%), Neuroscience (29%), Chemistry (8%). It does 1.6× the world's share of Life Sciences.

Health Sciences: 6 fractional works · 46.3% of its workMedicine: 6 fractional works · 45.2% of its workHematology: 1 fractional works · 4.9% of its workEpidemiology: 1 fractional works · 4.2% of its workPsychiatry and Mental health: 1 fractional works · 4.2% of its workGenetics: 0 fractional works · 3.7% of its workPhysiology: 0 fractional works · 3.5% of its workNeurology: 0 fractional works · 3.4% of its workPharmacology: 0 fractional works · 3.2% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 2.8% of its workComplementary and alternative medicine: 0 fractional works · 2.4% of its workPediatrics, Perinatology and Child Health: 0 fractional works · 2.4% of its workHepatology: 0 fractional works · 2.1% of its workGeriatrics and Gerontology: 0 fractional works · 1.8% of its workInfectious Diseases: 0 fractional works · 1.8% of its workOncology: 0 fractional works · 1.1% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 1.1% of its workNephrology: 0 fractional works · 0.6% of its workPulmonary and Respiratory Medicine: 0 fractional works · 0.6% of its workBiochemistry: 0 fractional works · 0.5% of its workRehabilitation: 0 fractional works · 0.4% of its workAnesthesiology and Pain Medicine: 0 fractional works · 0.3% of its workNursing: 0 fractional works · 0.6% of its workNutrition and Dietetics: 0 fractional works · 0.6% of its workHealth Professions: 0 fractional works · 0.5% of its workHealth Information Management: 0 fractional works · 0.5% of its workLife Sciences: 5 fractional works · 37.9% of its workNeuroscience: 4 fractional works · 28.6% of its workCellular and Molecular Neuroscience: 2 fractional works · 11.9% of its workNeurology: 1 fractional works · 10.4% of its workBehavioral Neuroscience: 0 fractional works · 2.4% of its workCognitive Neuroscience: 0 fractional works · 1.6% of its workDevelopmental Neuroscience: 0 fractional works · 1.4% of its workBiological Psychiatry: 0 fractional works · 0.8% of its workBiochemistry, Genetics and Molecular Biology: 1 fractional works · 6.3% of its workMolecular Biology: 1 fractional works · 4.3% of its workGenetics: 0 fractional works · 0.8% of its workClinical Biochemistry: 0 fractional works · 0.5% of its workCancer Research: 0 fractional works · 0.4% of its workBiochemistry: 0 fractional works · 0.3% of its workImmunology and Microbiology: 0 fractional works · 1.6% of its workApplied Microbiology and Biotechnology: 0 fractional works · 0.8% of its workImmunology: 0 fractional works · 0.8% of its workAgricultural and Biological Sciences: 0 fractional works · 1.4% of its workFood Science: 0 fractional works · 0.8% of its workEcology, Evolution, Behavior and Systematics: 0 fractional works · 0.6% of its workPhysical Sciences: 1 fractional works · 8.8% of its workChemistry: 1 fractional works · 7.9% of its workSpectroscopy: 1 fractional works · 7.4% of its workOrganic Chemistry: 0 fractional works · 0.6% of its workEnvironmental Science: 0 fractional works · 0.8% of its workPollution: 0 fractional works · 0.8% of its workSocial Sciences: 1 fractional works · 7.1% of its workEconomics, Econometrics and Finance: 0 fractional works · 3.7% of its workEconomics and Econometrics: 0 fractional works · 3.7% of its workBusiness, Management and Accounting: 0 fractional works · 1.8% of its workStrategy and Management: 0 fractional works · 1.8% of its workPsychology: 0 fractional works · 1.5% of its workSocial Psychology: 0 fractional works · 1.5% of its workALL ITS WORKAsarina Pharma(Sweden)14fractional works, all years
Life Sciences38%Physical Sciences9%Health Sciences46%Social Sciences7%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 12 fields, with their numbers
    1. Medicine645.2%
    2. Nursing00.6%
    3. Health Professions00.5%
    1. Neuroscience428.6%
    2. Biochemistry, Genetics and Molecular Biology16.3%
    3. Immunology and Microbiology01.6%
    4. Agricultural and Biological Sciences01.4%
    1. Chemistry17.9%
    2. Environmental Science00.8%
    1. Economics, Econometrics and Finance03.7%
    2. Business, Management and Accounting01.8%
    3. Psychology01.5%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.26× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 1.10× its world share, 0 worksBiochemistry, Geneti…Immunology and Microbiology: 1.62× its world share, 0 worksImmunology and Micro…Neuroscience: 22.95× its world share, 2 worksNeuroscienceChemistry: 0.78× its world share, 0 worksChemistryMedicine: 2.56× its world share, 3 worksMedicineNursing: 2.49× its world share, 0 worksNursingPsychology: 0.80× its world share, 0 worksPsychology1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Neuroscience, 22.9×. Every wedge is a field page.

All 8 fields, with their numbers
  1. Neuroscience22.95×2 works
  2. Medicine2.56×3 works
  3. Nursing2.49×0 works
  4. Immunology and Microbiology1.62×0 works
  5. Biochemistry, Genetics and Molecular Biology1.10×0 works
  6. Psychology0.80×0 works
  7. Chemistry0.78×0 works
  8. Agricultural and Biological Sciences0.26×0 works

What are the most cited papers from Asarina Pharma (Sweden)?

The most cited paper from Asarina Pharma (Sweden) is "Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)—A randomized controlled trial" (Marie Bixo, Karin Ekberg, Inger Sundström Poromaa et al., 2017), with 132 citations. Next come "Acceleration of Amyloidosis by Inflammation in the Amyloid-Beta Marmoset Monkey Model of Alzheimer’s Disease" (78) and "GR3027 antagonizes GABA A receptor-potentiating neurosteroids and restores spatial learning and motor coordination in rats with chronic hyperammonemia and hepatic encephalopathy" (76).

Most cited papers
#PaperReleasedCitations
1 Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)—A randomized controlled trial Marie Bixo, Karin Ekberg, Inger Sundström Poromaa et al. · Psychoneuroendocrinology Open access 2 Mar 2017 132
2 Acceleration of Amyloidosis by Inflammation in the Amyloid-Beta Marmoset Monkey Model of Alzheimer’s Disease Ingrid H.C.H.M. Philippens, Paul R. Ormel, Guus Baarends et al. · Journal of Alzheimer s Disease Open access 20 Sep 2016 78
3 GR3027 antagonizes GABA A receptor-potentiating neurosteroids and restores spatial learning and motor coordination in rats with chronic hyperammonemia and hepatic encephalopathy Maja Johansson, Ana Agustí, Marta Llansola et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology Open access 3 Jul 2015 76
4 A pilot study of golexanolone, a new GABA-A receptor-modulating steroid antagonist, in patients with covert hepatic encephalopathy Sara Montagnese et al. · Journal of Hepatology Open access 21 Apr 2021 58
5 Incidence of hemorrhagic stroke in the general population: validation of data from The Health Improvement Network David Gaist, Mari-Ann A. Wallander, Antonio González‐Pérez et al. · Pharmacoepidemiology and Drug Safety 10 Dec 2012 52
All 27 most cited papers, with filters and sorting

Which research topics does Asarina Pharma (Sweden) publish most on?

By volume in 2022-now: Neuroscience and Neuropharmacology Research, Neuroinflammation and Neurodegeneration Mechanisms, Chronic Myeloid Leukemia Treatments and Liver Disease Diagnosis and Treatment.

Neuroscience and Neuroph…1Neuroscience and Neuropharmacology Research: 1 fractional worksNeuroinflammation and Ne…1Neuroinflammation and Neurodegeneration Mechanisms: 1 fractional worksChronic Myeloid Leukemia…0Chronic Myeloid Leukemia Treatments: 0 fractional worksLiver Disease Diagnosis …0Liver Disease Diagnosis and Treatment: 0 fractional worksParkinson's Disease Mechanisms and Treatments: 0 fractional worksChronic Lymphocytic Leukemia Research: 0 fractional worksNuclear Receptors and Si…0Nuclear Receptors and Signaling: 0 fractional worksPrenatal Screening and Diagnostics: 0 fractional worksStress Responses and Cortisol: 0 fractional worksInfectious Encephalopathies and Encephalitis: 0 fractional works
Cellular and Molecular NeuroscienceNeurologyHematologyEpidemiology4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Neuroscience and Neuropharmacology Research Cellular and Molecular Neuroscience 1 works
  2. 2 Neuroinflammation and Neurodegeneration Mechanisms Neurology 1 works
  3. 3 Chronic Myeloid Leukemia Treatments Hematology 0 works
  4. 4 Liver Disease Diagnosis and Treatment Epidemiology 0 works
  5. 5 Parkinson's Disease Mechanisms and Treatments Neurology 0 works
  6. 6 Chronic Lymphocytic Leukemia Research Genetics 0 works
  7. 7 Nuclear Receptors and Signaling Cellular and Molecular Neuroscience 0 works
  8. 8 Prenatal Screening and Diagnostics Pediatrics, Perinatology and Child Health 0 works
  9. 9 Stress Responses and Cortisol Behavioral Neuroscience 0 works
  10. 10 Infectious Encephalopathies and Encephalitis Infectious Diseases 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available63.4%not open36.6%

World: 40% of research is openly available.

with international co-authors45.5%domestic only54.5%

World: 18% is written across borders.

How has Asarina Pharma (Sweden)'s research output changed?

Output in 2022-2025 was 876% higher than in 2018-2021.

still counting1990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Asarina Pharma (Sweden) as a percentage of every work published that year, 0.000030% in 2024.

still counting0.00010%0.00020%Asarina Pharma (Sweden)0.000037% in 20251990200020102020

Fractional works of Asarina Pharma (Sweden) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Solna

All research institutions in Solna

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Asarina Pharma (Sweden). Posts are plain text and can be reported.